Accessibility Menu
Cogstate logo

Cogstate(OTC) COGZF

Market Cap$407.81MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2010)+773%
5 Year+115%
1 Year+143%
1 Month+21%
$2.40
+14.29%
+0.30Today
Cogstate last closing stock price
MetricPriceDate
Last closeUSD 2.402026-08-20
Cogstate stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+28%USD 1.882026-08-10
1 month+20.6%USD 1.992026-07-09
3 month+29.03%USD 1.862026-05-22
Year to date+50%USD 1.602025-12-23
1 year+142.71%USD 0.992025-08-18
3 year+169.68%USD 0.892023-08-21
5 year+114.79%USD 1.122021-08-20
Since inception+772.73%USD 0.282010-03-25

Cogstate Financials at a Glance

Market Cap

$407.81MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$112.50M

Net Income (TTM)

$22.19M

EPS (TTM)

$0.07

P/E Ratio

34.48

Dividend

$0.01

Beta (Volatility)

0.45 (Low)

Price

$2.40

Volume

550

Open

$2.40

Previous Close

$2.40

Daily Range

$2.40 - $2.40

52-Week Range

$1.05 - $2.40

Estimated Earnings Date

Feb 24, 2027

COGZF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cogstate

Cogstate Limited is a neuroscience technology firm based in Melbourne, Australia, specializing in digital cognitive assessments and electronic solutions for evaluating clinical outcomes. Established in 1999, the company serves both the Clinical Trials and Healthcare sectors, providing innovative tools for measuring cognitive function.

Products and Services
  • Digital cognitive assessments for clinical trials
  • Cognigram, a system for early cognitive impairment detection
  • Comprehensive project and data management services
Growth Outlook
  • Recent quarterly revenue reached $26.2 million, indicating strong demand
  • Net income for the latest quarter was $4.6 million, showcasing profitability
  • Continued expansion in clinical trials and healthcare sectors expected
Financial Highlights
  • Trailing twelve-month revenue of $102.5 million reflects consistent growth
  • Net profit margin of 19.6% demonstrates effective cost management
  • Current ratio of 3.96 indicates strong liquidity position
Cogstate Limited has established itself as a leader in the neuroscience technology space, focusing on cognitive assessments that are crucial for both clinical trials and healthcare applications. The company's innovative products, such as Cognigram, are designed to assist healthcare providers in identifying cognitive impairments early, which is increasingly important in an aging population. The growth outlook for Cogstate appears promising, with recent financial results indicating a robust demand for its services. The latest quarterly revenue of $26.2 million and a net income of $4.6 million highlight the company's ability to generate profit while expanding its market presence. Furthermore, the trailing twelve-month revenue of $102.5 million underscores the company's consistent growth trajectory. Financially, Cogstate maintains a strong liquidity position, as evidenced by a current ratio of 3.96, which suggests that the company can easily meet its short-term obligations. The net profit margin of 19.6% reflects effective cost management strategies, positioning the company favorably within the healthcare information services industry. Overall, Cogstate Limited presents a compelling opportunity for investors interested in the intersection of technology and healthcare.
AI Generated • Aug 5, 2026

Industry

Health Care Technology

Sector

Health Care

Employees

410

CEO

Bradley John O'Connor

Website

www.cogstate.com

Headquarters

Melbourne, VIC 3000, AU

COGZF Financials

Key Financial Metrics (TTM)

Gross Margin

33.72%

Operating Margin

20.54%

Net Income Margin

20.26%

Return on Equity

21.61%

Return on Capital

21.08%

Return on Assets

15.22%

Earnings Yield

2.90%

Dividend Yield

0.55%

Payout Ratio

17.92%

Stock Overview

Market Cap

$407.81MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

169.92M

Volume

550

Avg. Volume

1.07K

Financials (TTM)

Gross Profit

$46.58M

Operating Income

$26.71M

EBITDA

$32.12M

Operating Cash Flow

$21.62M

Capital Expenditure

-$801.24K

Free Cash Flow

$20.82M

Cash & ST Invst.

$34.73M

Total Debt

$358.66K

Cogstate Performance Analysis

Cogstate annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30USD 40,451,123-10.1%
20242024-06-30USD 43,427,7737.4%
20252025-06-30USD 53,090,85822.3%
20262026-06-30USD 58,585,87410.4%
Cogstate sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-313.0%
Q42025-06-3025.3%
Q22025-12-31-12.5%
Q42026-06-3023.1%
Cogstate annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30USD 0.02-52.5%
20242024-06-30USD 0.0355.9%
20252025-06-30USD 0.0685.1%
20262026-06-30USD 0.0715.1%
Cogstate sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-3112.0%
Q42025-06-3065.2%
Q22025-12-31-29.5%
Q42026-06-3056.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

$32.30M

+38.9%

Gross Profit

$12.48M

-8.8%

Gross Margin

38.64%

N/A

Market Cap

$407.81MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.55M

N/A

Employees

160

N/A

Net Income

$7.25M

+110.5%

EBITDA

$9.80M

+86.4%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

$34.73M

+72.9%

Total Debt

$358.66K

-20.0%

Accounts Receivable

$22.42M

+233.5%

Inventory

$0.00

N/A

Long Term Debt

$240.50K

-20.7%

Short Term Debt

$118.15K

-45.8%

Return on Assets

15.22%

N/A

Return on Invested Capital

19.61%

N/A

Free Cash Flow

$6.19M

+3.2%

Operating Cash Flow

$6.31M

+1.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CLVLFClinuvel Pharmaceuticals Limited
$7.27+0.00%
EDTXFSpectral Medical Inc
$0.97-4.51%
CMVLFCellectis S.A.
$3.47+12.66%

Trending Stocks

Symbol / CompanyPricePrice Chg
IBITiShares Bitcoin Trust
$43.91+0.07%
BITOProShares Trust - ProShares Bitcoin ETF
$10.47+0.07%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.83+0.11%
MARAMara Holdings
$11.28+0.01%

Questions About COGZF

What is the current price of Cogstate?

Cogstate is trading at $2.40 per share.

What is the 52-week range for Cogstate?

Over the past 52 weeks, Cogstate has traded between $1.05 and $2.40.

How much debt does Cogstate have?

As of the most recent reporting period, Cogstate reported total debt of $359.18K.

How much cash does Cogstate have on hand?

Cogstate reported $34.78M in cash and cash equivalents in its most recent financial results.

What is Cogstate’s dividend yield?

Cogstate currently has a dividend yield of 0.55%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services